On Wednesday, Following Stocks were among the “Top 100 Losers” of U.S. Stock Market: Athersys, Inc. (NASDAQ:ATHX), TherapeuticsMD, Inc. (NYSEMKT:TXMD), Arrow Electronics, Inc. (NYSE:ARW), Christopher & Banks Corporation (NYSE:CBK)
Athersys, Inc. (NASDAQ:ATHX), with shares declined -11.42%, closed at $2.87.
TherapeuticsMD, Inc. (NYSEMKT:TXMD), with shares dropped -11.51%, settled at $5.92.
Arrow Electronics, Inc. (NYSE:ARW), with shares dipped -4.07%, and closed at $61.35.
Christopher & Banks Corporation (NYSE:CBK), plummeted -9.73%, and closed at $5.29.
Latest NEWS regarding these Stocks are depicted underneath:
Athersys, Inc. (NASDAQ:ATHX)
Athersys, Inc. (ATHX), took part in the 12th annual BIO Asia International Conference held on March 24-25, 2015 at the Grand Hyatt, Tokyo, Japan. Athersys was additionally a conference sponsor.
Gil Van Bokkelen, Chairman and Chief Executive Officer, took part on two panels, “Accelerating Innovation: Lessons from Regenerative Medicine Policy Reforms” on Tuesday, March 24th from 4:00 - 4:55 PM, and “Emerging Deal Making Trends” on Wednesday, March 25th from 9:00 — 9:55 AM, both of which took place in the Coriander conference room of the hotel. In addition, Dr. Van Bokkelen made a corporate presentation on Tuesday, March 24th at 1:45 PM in the Drawing Room.
Athersys, Inc., a biotechnology corporation, focuses on the research and development activities in the field of regenerative medicine. The corporations lead platform product, MultiStem cell therapy, an allogeneic stem cell product, which is in Phase II clinical trials for the treatment of ischemic stroke and inflammatory bowel disease (IBD); and that has accomplished Phase I clinical trial for the treatment of acute myocardial infarction and hematopoietic stem cell transplant/graft-as compared to-host disease.
TherapeuticsMD, Inc. (NYSEMKT:TXMD)
Formerly on March 18, TherapeuticsMD, Inc. (TXMD), declared the appointment of two biopharmaceutical senior executives, Angus C. Russell and J. Martin Carroll, as independent members of its board of directors, and that Randall S. Stanicky has stepped down from the board of directors.
Angus C. Russell served as CEO of Shire PLC, a biopharmaceutical corporation, from June 2008 until April 2013. Russell served as the chief financial officer of Shire from 1999 to 2008 and also served as executive vice president of global finance. Preceding to joining Shire, Russell served at ICI, Zeneca and AstraZeneca PLC for 19 years, most recently in the role of vice president, corporate finance at AstraZeneca. He is a chartered accountant, having qualified with what is now PriceWaterhouseCoopers LLP. Russell also serves as a director of Mallinckrodt PLC and BioTime Inc. and as the chairman of the board of Revance Therapeutics Inc. Russell formerly served as a director of Shire PLC, Questcor Pharmaceuticals Inc. and InterMune Inc.
- Martin Carroll served as president and CEO of Boehringer Ingelheim Corp. (U.S.) from 2003 until 2011. He also served as global head of strategy and development for Boehringer Ingelheim (Germany) from 2009 through 2012 and served as chairman of the board for a number of BI companies. Formerly, Carroll held positions of increasing responsibility with Merck & Co. Inc. from 1976 to 2001, counting manufacturing, international (Japan) and marketing and sales. He left Merck serving as its executive vice president for customer marketing and sales of the U.S. Human Health Division. From 1972 to 1976, Carroll served in the United States Air Force. Carroll has formerly served on the board of directors for a number of organizations, counting Accredo Health Group Inc., Vivus Inc., Durata Therapeutics Inc., and Gwynedd Mercy College, in addition to PhRMA. He presently serves as a director of Mallinckrodt PLC.
“We are very happy to add two new independent directors to our board. These biopharmaceutical industry leaders have a wealth of experience in both serving as directors and in practical senior leadership responsibilities at successful organizations,” said TherapeuticsMD CEO Robert G. Finizio. “This is an exciting time in our corporation’s growth and development, and we look forward to the insight of Angus and Marty.”
TherapeuticsMD, Inc. operates as a women’s health care product corporation. The corporation manufactures and distributes prescription and over-the-counter product lines, counting prenatal vitamins, iron supplements, vitamin D supplements, and natural menopause relief products under the vitaMedMD brand, in addition to duplicate formulations of its prescription prenatal vitamins products under the BocaGreenMD Prena1 name.
Arrow Electronics, Inc. (NYSE:ARW)
Arrow Electronics, Inc. (ARW), will distribute the StorMagic SvSAN virtual storage appliance to its broad community of solution providers in the United States and Canada. StorMagic is a provider of software-defined storage for virtual server environments.
The StorMagic SvSAN solution serves any small business or enterprise remote location running critical applications on-site, without dedicated local IT resources. Whether it’s a college campus, doctor’s office, a retail business with several brick and mortar locations, or a remote, unmanned wind energy farm, these organizations typically face similar storage challenges. This comprises ensuring availability and uptime, maximizing server and storage utilization, reducing cost and complexity, simplifying and centralizing administration and minimizing deployment costs. To assist achieve the lowest ownership costs, StorMagic SvSAN delivers virtualized shared storage that works with any 2-node x86 server set up, eliminating the need for physical SANs, and can be managed from a central location.
Established in 2006, StorMagic (www.stormagic.com) is a leading provider of virtual storage software solutions that enable organizations of all sizes to eliminate downtime of critical applications in all locations and lower their cost of IT by up to 40 percent.
Arrow Electronics, Inc. provides products, services, and solutions to industrial and commercial users of electronic components and enterprise computing solutions worldwide. The corporation operates in two segments, Global Components and Global Enterprise Computing Solutions.
Christopher & Banks Corporation (NYSE:CBK)
Christopher & Banks Corporation (CBK), stated results for the thirteen week period and fiscal year ended January 31, 2015.
Results for the Thirteen Week Period Ended January 31, 2015:
- Net sales totaled $98.0 million, as contrast to $104.9 million for the thirteen weeks ended February 1, 2014. During the quarter, the Corporation operated an average of 7.0% fewer stores than during the comparable period last year, reflecting its MPW store conversion program.
- Gross margin was 29.1% contrast to 32.5% in the fourth quarter of fiscal 2013, which comprises a 370-basis point negative influence for an error correction related to deferred rent expense, which is described below.
- Operating loss was $6.0 million for the thirteen week period ended January 31, 2015, which comprises a $3.6 million negative influence from the error correction. This compares to an operating loss of $0.5 million in the fourth quarter of fiscal 2013.
- Net revenue totaled $32.2 million, or $0.86 per diluted share, which comprised of a $41.3 million, or $1.10 per diluted share, reversal of our valuation allowance related to deferred revenue taxes and the influence of the error correction of $2.2 million, or $0.06 per diluted share. Net loss for the thirteen weeks ended February 1, 2014 totaled $0.3 million, or $0.01 per diluted share.
In connection with the preparation of the merged financial statements for the fiscal year ended January 31, 2015, the Corporation determined that its calculation of deferred rent expense was incorrect. The Corporation corrected the error in the fourth quarter of fiscal 2014, which resulted in a cumulative raise to rent expense of about $3.6 million. There was no influence to net cash offered by operating activities. The Corporation has concluded that this correction is immaterial to the related merged financial statements as a whole.
Christopher & Banks Corporation, through its auxiliaries, operates as a retailer of women’s apparel and accessories in the United States. It designs, sources, and sells women’s apparel and accessories to customers ranging in age from 45 to 60. The corporation’s stores offer women’s apparel comprising of knit tops, woven tops, jackets, sweaters, skirts, denim bottoms, bottoms made of other fabrications, and dresses in missy, petite, and women sizes, in addition to jewelry and accessories.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
